Verséa Ophthalmics Inc. is on a mission to transform and personalize clinical and therapeutic decisions in eye care. The company focuses on delivering an innovative Tear-based Point-of-Care (T-POC) quantitative testing platform and biologic solutions that optimize diagnosis, treatment, and management of various conditions, including ocular surface disease such as persistent epithelial defects , corneal dystrophies, and neurotropic keratitis as well as surgical conditions such as pterygium excision, conjunctivochalasis, and glaucoma tube shunts.
A newly launched product portfolio consists of a novel, Tear-based, Point-of-Care (T-POC) quantitative testing platform and complementary allograft therapeutics that will enhance clinical management and inform treatment decisions that ultimately lead to better patient care.
Verséa Ophthalmics is committed to supporting Eye Care Professionals with diagnosis, management, and treatment of patients with ocular surface diseases or requiring ocular surgery.
Click to Enlarge Image
Verséa is a registered trademark of Verséa Health, Inc.
©2024 Verséa Ophthalmics, Inc. All rights reserved.
© 2024 Verséa Health, Inc. All rights reserved.